Wei, X. et al. Viral dynamics in human immunodeficiency virus type I infection. Nature 373, 117−122
ABSTRACT The dynamics of HIV-1 replication in vivo are largely unknown yet they are critical to our understanding of disease pathogenesis. Experimental drugs that are potent inhibitors of viral replication can be used to show that the composite lifespan of plasma virus and virus-producing cells is remarkably short (half-life approximately 2 days). Almost complete replacement of wild-type virus in plasma by drug-resistant variants occurs after fourteen days, indicating that HIV-1 viraemia is sustained primarily by a dynamic process involving continuous rounds of de novo virus infection and replication and rapid cell turnover.
- SourceAvailable from: Abdon Atangana
[Show abstract] [Hide abstract]
- "The infection results in high T-cell activation and turnover. An immediately intuitive assumption is that HIV-mediated destruction of CD4 + cells directly reduces the number of these cells and that the high turnover rates of T cells and the slow progression to AIDS reflect a long but eventually lost struggle of the immune system to replace killed cells in its effort to maintain T-cell homeostasis    . However, HIV mainly infects activated CD4 + cells, and activated cells normally follow different dynamics than cells that belong to resting populations whose numbers are controlled by homeostatic mechanisms. "
ABSTRACT: An analysis of the model underpinning the description of the spread of HIV infection of CD4 + T cells is examined in detail in this work. Investigations of the disease free and endemic equilibrium are done using the method of Jacobian matrix. An iteration technique, namely, the homotopy decomposition method (HDM), is implemented to give an approximate solution of nonlinear ordinary differential equation systems. The technique is described and illustrated with numerical examples. The approximated solution obtained via HDM is compared with those obtained via other methods to prove the trustworthiness of HDM. Moreover, the lessening and simplicity in calculations furnish HDM with a broader applicability.BioMed Research International 06/2014; 2014(2014):10. DOI:10.1155/2014/618404 · 2.71 Impact Factor
[Show abstract] [Hide abstract]
- "The genetic diversity of HIV within a patient is large as HIV is prone to errors during replication (Overbaugh and Bangham, 2001; Rambaut et al., 2004). Furthermore, the virus population has a high turnover with a mean half-life of 1–2 days (Coffin, 1995; Ho et al., 1995; Perelson et al., 1996; Wei et al., 1995). The high heritability , the fitness differences between virus genotypes, the large virus population size within a host, the high mutation rate and the short generation time together lead to the expectation that within-host evolution should lead to higher viral loads over the long duration of the asymptomatic phase (Read and Taylor, 2001). "
ABSTRACT: The asymptomatic phase of HIV-1 infections is characterised by a stable set-point viral load (SPVL) within patients. The SPVL is a strong predictor of disease progression and shows considerable variation of multiple orders of magnitude between patients. Recent studies have found that the SPVL in donor and recipient pairs is strongly correlated indicating that the virus genotype strongly influences viral load. Viral genetic factors that increase both viral load and the replicative capacity of the virus would result in rapid within-host evolution to higher viral loads. Reconciling a stable SPVL over time with high SPVL heritability requires viral genetic factors that strongly influence SPVL but only weakly influence the competitive ability of the virus within hosts. We propose a virus trait that affects the activation of target cells, and therefore viral load, but does not confer a competitive advantage to the virus. We incorporate this virus-induced target cell activation into within- and between-host models and determine its effect on the competitive ability of virus strains and on the variation in SPVL in the host population. On the within-host level, our results show that higher rates of virus-induced target cell activation increase the SPVL and confer no selective advantage to the virus. This leads to a build up of diversity in target cell activation rates in the virus population during within-host evolution. On the between-host level, higher rates of target cell activation and therefore higher SPVL affect the transmission potential of the virus. Random selection of a new founder strain from the diverse virus population within a donor results in a standing variation in SPVL in the host population. Therefore, virus-induced target cell activation can explain the heritability of SPVL, the absence of evolution to higher viral loads during infection and a large standing variation in SPVL between hosts.12/2013; 5(4):174-180. DOI:10.1016/j.epidem.2013.09.002
[Show abstract] [Hide abstract]
- "The composite lifespan of plasma virus and virusproducing cells is very short with a half-life of approximately two days, and an almost complete replacement of wild-type strains by drug resistant virus occurs in plasma within 2– 4 weeks . During antiretroviral treatment, rapid viral turnover in combination with a high mutation rate is a primary factor behind the emergence of HIV variants with antiretroviral drug resistance. "
ABSTRACT: Despite advances in antiretroviral therapy that have revolutionized HIV disease management, effective control of the HIV infection pandemic remains elusive. Beyond the classic non-B endemic areas, HIV-1 non-B subtype infections are sharply increasing in previous subtype B homogeneous areas such as Europe and North America. As already known, several studies have shown that, among non-B subtypes, subtypes C and D were found to be more aggressive in terms of disease progression. Luckily, the response to antiretrovirals against HIV-1 seems to be similar among different subtypes, but these results are mainly based on small or poorly designed studies. On the other hand, differences in rates of acquisition of resistance among non-B subtypes are already being observed. This different propensity, beyond the type of treatment regimens used, as well as access to viral load testing in non-B endemic areas seems to be due to HIV-1 clade specific peculiarities. Indeed, some non-B subtypes are proved to be more prone to develop resistance compared to B subtype. This phenomenon can be related to the presence of subtype-specific polymorphisms, different codon usage, and/or subtype-specific RNA templates. This review aims to provide a complete picture of HIV-1 genetic diversity and its implications for HIV-1 disease spread, effectiveness of therapies, and drug resistance development.06/2013; 2013(4599):481314. DOI:10.1155/2013/481314